( NASDAQ-SMALL:CAPR )

News from Capricor Therapeutics, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 15, 2017, 12:00 ET Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor's Investigational Cell Therapy

Boys and young men in advanced stages of Duchenne muscular dystrophy experienced significant and sustained improvements in cardiac structure and...


Nov 08, 2017, 16:01 ET Capricor Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Duchenne Muscular Dystrophy Development Program

Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced its financial results for the third quarter ended September 30, 2017 and provided an...


Nov 01, 2017, 16:30 ET Capricor Therapeutics Third Quarter 2017 Update Webcast and Conference Call Scheduled for Wednesday, November 8

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare...


Oct 25, 2017, 07:00 ET Capricor Announces 12-Month Results from HOPE-1 Trial in Duchenne Muscular Dystrophy to be Presented at AHA Late-Breaking Session

Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced that the American Heart Association (AHA) Scientific Sessions 2017 has accepted for...


Oct 06, 2017, 09:00 ET Capricor Therapeutics Reports Intravenous Administration of CAP-1002 Shown to be Effective in Preclinical Models of Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. (NASDAQ: CAPR), in a poster presentation at the Alliance for Regenerative Medicine's Cell and Gene Meeting on the Mesa,...


Oct 04, 2017, 07:00 ET Capricor Therapeutics Presents Positive Six-Month Results in Duchenne Muscular Dystrophy at World Muscle Society International Congress

Capricor Therapeutics, Inc. (NASDAQ: CAPR), in its presentation today at the 22nd Annual International Congress of the World Muscle Society,...


Sep 26, 2017, 07:00 ET Capricor Therapeutics Advances Clinical Development Program in Duchenne Muscular Dystrophy with Naming of Principal Investigator

Capricor Therapeutics, Inc. (NASDAQ: CAPR), which is developing biological therapies for Duchenne muscular dystrophy (DMD) and other rare diseases,...


Sep 18, 2017, 07:00 ET Capricor Therapeutics to Present Six-Month Results from the Randomized HOPE Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy (DMD) and other...


Aug 10, 2017, 16:05 ET Capricor Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update

Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced its financial results for the second quarter ended June 30, 2017 and provided an update...


Aug 03, 2017, 16:05 ET Capricor Therapeutics Second Quarter 2017 Update Webcast and Conference Call Scheduled for Thursday, August 10

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare...


Jul 27, 2017, 06:00 ET Capricor Announces Results of FDA Meeting on Intravenous CAP-1002 for Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy (DMD) and other...


Jul 18, 2017, 08:00 ET Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare...


Jul 06, 2017, 18:30 ET Capricor Therapeutics Retains Full Rights to CAP-1002 as Janssen Biotech, Inc. Decides Not to Exercise Option

Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced that Janssen Biotech, Inc. (Janssen) has decided not to exercise its option to...


Jun 29, 2017, 09:00 ET Six-Month Results from Capricor's HOPE-Duchenne Trial to be Presented at the 2017 PPMD Annual Connect Conference

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other...


Jun 15, 2017, 14:00 ET Capricor Therapeutics to Present at 2017 BIO International Convention

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other...


Jun 01, 2017, 08:00 ET Capricor Therapeutics to Present at the LD Micro Invitational Conference on June 6

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other...


May 31, 2017, 07:00 ET Capricor Therapeutics Announces Upcoming Events in Duchenne Muscular Dystrophy Program

Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced that a formal meeting between Capricor and the U.S. Food and Drug Administration (FDA),...


May 25, 2017, 09:00 ET Capricor Therapeutics Announces Formation of Duchenne Muscular Dystrophy Advisory Board

Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced that, in connection with its growing commitment to the development of CAP-1002 for...


May 15, 2017, 16:15 ET Capricor Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update

Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced its financial results for the first quarter ended March 31, 2017 and provided an update...


May 12, 2017, 06:30 ET Capricor Therapeutics Provides Update on ALLSTAR Trial

Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced that a pre-specified administrative interim analysis performed on six-month follow-up...


May 08, 2017, 08:00 ET Capricor Therapeutics Announces Private Placement of Common Stock

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing first-in-class biological therapies for cardiac and...


May 04, 2017, 16:00 ET Capricor Therapeutics to Hold First Quarter 2017 Financial Results and Corporate Update Conference Call on Monday, May 15

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing first-in-class biological therapies for cardiac and...


Apr 26, 2017, 08:00 ET Capricor Therapeutics to Present at the Alliance for Regenerative Medicine's Cell & Gene Therapy Investor Day

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing first-in-class biological therapies for cardiac and...


Apr 25, 2017, 06:00 ET Capricor Therapeutics Announces Positive Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing first-in-class biological therapies for cardiac and...


Apr 24, 2017, 16:30 ET Capricor Therapeutics to Report Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing first-in-class biological therapies for cardiac and...